Company Description
Aquestive Therapeutics, Inc. operates as a pharmaceutical company in the United States and internationally.
The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder; and Libervant, a buccal soluble film formulation of diazepam for the treatment of seizures.
The company’s proprietary pipeline of complex molecule products includes AQST-108, which is in phase 2, a sublingual film formulation delivering systemic epinephrine for the treatment of conditions other than anaphylaxis; and Anaphylm, which is in phase 3, an epinephrine sublingual film for the emergency treatment of allergic reactions, including anaphylaxis.
In addition, it develops PharmFilm technology for patients suffering from certain central nervous system disorders and Adrenaverse, an epinephrine prodrug platform.
The company was incorporated in 2004 and is headquartered in Warren, New Jersey.
| Country | United States |
| Founded | 2004 |
| IPO Date | Jul 25, 2018 |
| Industry | Drug Manufacturers - Specialty & Generic |
| Sector | Healthcare |
| Employees | 142 |
| CEO | Daniel Barber |
Contact Details
Address: 30 Technology Drive Warren, New Jersey 07059 United States | |
| Phone | 908 941 1900 |
| Website | aquestive.com |
Stock Details
| Ticker Symbol | AQST |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001398733 |
| CUSIP Number | 03843E104 |
| ISIN Number | US03843E1047 |
| Employer ID | 20-8623253 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Daniel Barber | Chief Executive Officer, President and Director |
| A. Ernest Toth Jr. | Chief Financial Officer |
| Lori J. Braender BSBA, Esq., J.D. | Chief Legal Officer, Chief Compliance Officer &Secretary |
| Cassie Jung | Chief Operating Officer |
| Dr. Stephen Wargacki Ph.D. | Chief Science Officer |
| Sherry Korczynski | Senior Vice President of Sales and Marketing |
| Peter E. Boyd | Senior Vice President of Information Technology and Human Resources |
| Dr. Gary H. Slatko M.D., MBA | Chief Medical Officer |
| Dr. Carl N. Kraus M.D. | Chief Medical Officer |
| Robert Charles Arnold | Vice President of Finance, Controller and Assistant Secretary |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Mar 10, 2025 | 8-K | Current Report |
| Mar 5, 2025 | 10-K | Annual Report |
| Mar 5, 2025 | 8-K | Current Report |
| Feb 14, 2025 | SCHEDULE 13G/A | Filing |
| Feb 13, 2025 | SCHEDULE 13G/A | Filing |
| Feb 12, 2025 | 8-K | Current Report |
| Jan 24, 2025 | S-8 | Securities to be offered to employees in employee benefit plans |
| Jan 13, 2025 | 8-K | Current Report |
| Dec 19, 2024 | 8-K | Current Report |
| Dec 2, 2024 | 8-K | Current Report |